Galderma Group AG
A Study to Evaluate the Safety Following Injection of GP0045 Compared to Restylane Lyft Lidocaine
- First Posted Date
- 2017-04-28
- Last Posted Date
- 2022-08-25
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 12
- Registration Number
- NCT03133325
- Locations
- 🇸🇪
CTC, Uppsala, Sweden
Performance and Safety of Restylane Lidocaine for Treatment of Depressed Facial Acne Scars
- Conditions
- Interventions
- First Posted Date
- 2017-04-25
- Last Posted Date
- 2022-08-26
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 49
- Registration Number
- NCT03127384
- Locations
- 🇩🇪
Munich, Munich, Germany
🇩🇪Darmstadt, Darmstadt, Germany
Dose-ranging Study of Nemolizumab in Atopic Dermatitis
- First Posted Date
- 2017-04-04
- Last Posted Date
- 2019-10-22
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 226
- Registration Number
- NCT03100344
- Locations
- 🇺🇸
Galderma Investigational site, Richmond, Virginia, United States
🇵🇱Galderma Investigational Site, Łódź, Poland
Restylane Perlane Lidocaine for Correction of Midface Volume Deficit and/or Midface Contour Deficiency
- Conditions
- Interventions
- First Posted Date
- 2017-03-31
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 169
- Registration Number
- NCT03097783
- Locations
- 🇨🇳
Q-Med AB, Shanghai, China
Oracea Soolantra Association in Participants With Severe Rosacea
- Conditions
- Interventions
- First Posted Date
- 2017-03-09
- Last Posted Date
- 2021-03-16
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 273
- Registration Number
- NCT03075891
- Locations
- 🇺🇸
Private Practice, Metairie, Louisiana, United States
🇭🇺Private practice, Szolnok, Hungary
🇭🇺University, Szeged, Hungary
Efficacy and Safety of CD5024 1% in Acne Vulgaris
- Conditions
- Interventions
- First Posted Date
- 2017-01-27
- Last Posted Date
- 2020-12-11
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 70
- Registration Number
- NCT03034460
- Locations
- 🇨🇦
Galderma Investigational Site (# 8060), Windsor, Ontario, Canada
🇨🇦Galderma Investigational site, Montreal, Quebec, Canada
🇩🇪Galderma investigational site, Munster, Germany
Safety and Efficacy of CD10367 in Psoriasis Vulgaris
- Conditions
- Interventions
- First Posted Date
- 2017-01-19
- Last Posted Date
- 2017-04-05
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 24
- Registration Number
- NCT03025282
- Locations
- 🇫🇷
Galderma Investigational Site, Nice, France
Restylane Defyne Compared to Restylane for Correction of Moderate to Severe Nasolabial Folds
- Conditions
- Interventions
- First Posted Date
- 2016-12-26
- Last Posted Date
- 2023-11-03
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 175
- Registration Number
- NCT03003130
- Locations
- 🇨🇳
Q-Med AB, Shanghai, China
Efficacy and Safety Study of NP000888 in Subjects With Plaque and Nail Psoriasis
- First Posted Date
- 2016-12-16
- Last Posted Date
- 2018-06-12
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 61
- Registration Number
- NCT02995473
- Locations
- 🇨🇳
Galderma investigational site 5, Taipei, Taiwan
🇨🇳Galderma Investigational Site, Lincuo, Taoyuan, Taiwan
🇨🇳Galderma investigational site, Tainan, Taiwan
Subject Reported Outcomes With Use of Adapalene 0.3% - Benzoyl Peroxide (BPO) 2.5% in Dark Skin Acne
- First Posted Date
- 2016-10-13
- Last Posted Date
- 2021-02-18
- Lead Sponsor
- Galderma R&D
- Target Recruit Count
- 50
- Registration Number
- NCT02932267
- Locations
- 🇺🇸
Dermresearch, Austin, Texas, United States
🇸🇬CIDP, Singapore, Singapore